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Abstract
SH3 domains constitute a new type of ubiquitin-binding domains. We previously showed that the third SH3 domain
(SH3-C) of CD2AP binds ubiquitin in an alternative orientation. We have determined the structure of the complex
between first CD2AP SH3 domain and ubiquitin and performed a structural and mutational analysis to decipher the
determinants of the SH3-C binding mode to ubiquitin. We found that the Phe-to-Tyr mutation in CD2AP and in the
homologous CIN85 SH3-C domain does not abrogate ubiquitin binding, in contrast to previous hypothesis and our
findings for the first two CD2AP SH3 domains. The similar alternative binding mode of the SH3-C domains of these
related adaptor proteins is characterised by a higher affinity to C-terminal extended ubiquitin molecules. We conclude
that CD2AP/CIN85 SH3-C domain interaction with ubiquitin constitutes a new ubiquitin-binding mode involved in a
different cellular function and thus changes the previously established mechanism of EGF-dependent CD2AP/CIN85
mono-ubiquitination.
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Introduction
Adaptor molecules are non-catalytic polypeptides that
contain one or more domains able to bind to other proteins or
non-protein ligands [1]. These molecules selectively control the
spatial and temporal assembly of multi-protein complexes that
transmit intracellular signals involved in regulation of cell
growth, differentiation, migration and survival. The importance
of such signalling networks is well understood for signal
transduction induced by receptor tyrosine kinases (RTKs) [2].
Down regulation of RTKs is a critical step in modulating their
activity [3]. This is a highly ordered and dynamic process
controlled by the assembly of a large network of RTK-
associated proteins as well as their post-translational
modifications including phosphorylation and ubiquitination. The
Cbl family of ubiquitin ligases plays a major role in receptor
ubiquitination, receptor sorting for degradation and ultimately in
cessation of receptor-induced signal transduction. Several lines
of evidence support a role of CMS/CIN85 (Cas ligand with
Multiple SH3 domains/Cbl-Interacting protein of 85 kDa) in the
regulation of Cbl-directed RTK down regulation [4–7]. CMS,
also known as CD2AP (CD2 associated protein), shares overall
domain organization with CIN85, containing three SH3 (Src-
Homology) domains, a proline-rich region and a coiled-coiled
domain, and high sequence identity and hence, it has been
assumed to belong to the same family of ubiquitously
expressed adaptor molecules and elicit similar biological
functions. The three N-terminal SH3 domains, named A, B and
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C, share higher similarity among themselves than to any other
SH3 domain, suggesting that they may have overlapping
specificities in binding [8].
SH3 domains form a highly conserved family of protein
domains, but their amino acid composition varies at a few key
sites, allowing for a wide range of molecular targets. Similar to
SH3 domains, ubiquitin-binding domains (UBDs) are found in
proteins with different biological function. Structures of many
complexes between UBDs and ubiquitin have been determined
either by X-ray crystallography or high-resolution NMR
(reviewed in 9,10). Recently, SH3 domains were identified as a
new class of UBDs [11]. Since then, several low- and high-
resolution structural studies have raised a significant number of
unanswered questions concerning the determinants of the
specificity of the interaction between SH3 domains and
ubiquitin [12–15]. Moreover, several mechanistic differences
have been proposed for ubiquitin binding to SH3 domains
involved in the immune signalling pathway [16].
A key affinity and specificity determinant has been appointed
to Phe409 in Sla1 SH3-3 and the three SH3 domains of CIN85.
We recently used NMR residual dipolar couplings (RDCs) to
obtain the solution structure of the complex between ubiquitin
and the third (SH3-C) domain of CD2AP [15], and showed that
this SH3 domain binds ubiquitin in an alternative orientation.
In the current work, we have performed structural and
mutational analysis of the three SH3 domains of CD2AP and
the third SH3 domain of CIN85. We have found a distinct
ubiquitin-binding mode for the third SH3 domains of both
CD2AP and CIN85 adaptor proteins, in which i. the Phe
corresponding to Phe409 in Sla1 SH3-3 does not play a key
role, and ii. Is characterized by a higher affinity for ubiquitin that
is augmented by additional stretches of residues at the C-
terminus of ubiquitin. The differences in binding mode of SH3
domains to ubiquitin might be related to different functions
inside the cell. We propose that the CD2AP/CIN85 SH3-C
interaction with ubiquitin is related to selective binding to
ubiquitin molecules covalently bonded via its C-terminus in
ubiquitinated CD2AP and CIN85.
Materials and Methods
Protein expression and purification
Unlabelled, 15N-labelled and 13C,15N CD2AP SH3-A and C
were obtained as described elsewhere [17]. Unlabelled CD2AP
SH3-B was expressed as described previously [17]. Unlabelled
and 15N-labelled His-tagged and non His-tagged ubiquitin were
purchased from Spectra Isotopes or obtained as described in
[12] [18]. Protein concentrations were determined by UV-
absorption measurements at 280 nm using extinction
coefficients of 9970, 12660, 13980, 13980 and 1450 M-1 cm-1
for CD2AP SH3-A, B and C, CIN85 SH3-C and ubiquitin
respectively, determined using the ProtParam algorithm
(www.expasy.ch).
The genes encoding the mutants CD2AP F324Y SH3-C and
CIN85 F322Y SH3-C proteins were obtained by site-directed
mutagenesis using QuikChangeTM (Stratagene) kit. Mutant
proteins were over-expressed in E. Coli BL21/DE3 cells and
purified like the WT CD2AP SH3-C and WT CIN85 SH3-C
domains. F53Y CD2AP SH3-A mutant and CD2AP SH3-C
T283A and E302K + T303 deletion mutants were purchased
from Topgene and expressed as the WT domains. Both the
DNA sequence and molecular weight of the final purified
protein were checked to confirm the presence of every
mutation.
The CIN85-SH3C 270-328His6 was cloned in pET21a and
expressed in E. coli BL21 (DE3) grown in LB broth after 7
hours induction with 0.1 mM IPTG at 25°C. Cell pellets were
lysed by sonication with 50mM Tris pH 8.0, 200mM NaCl and
50mM Imidazole. After sonication, the lysate was subjected to
His-tag selection in a nickel charged HiTrap chelating column.
The protein was eluted in a 50-500 mM imidazole gradient.
After chelating the sample was diluted up to 20mM imidazole
and loaded into a Q FF HiTrap column (Ge Healthcare),
washed with 20mM Hepes pH 8.6 and eluted in a NaCl
gradient. Finally a size exclusion on a Superdex75 column
using 20mM Hepes pH 8.0, 100mM Nacl and 4% glycerol was
performed.
NMR chemical shift perturbation
All NMR titration experiments were recorded at 25°C on a
Varian NMR Direct-Drive 600 MHz spectrometer (1H frequency
of 600.25 MHz) equipped with a triple-resonance PFG-XYZ
probe. 15N labelled-CD2AP SH3-A and C samples and ubiquitin
were prepared in 92% H2O/8% D2O, 50 mM NaPi, 1 mM DTT
at pH 6.0. A HNCACB triple resonance spectrum was recorded
on a 13C,15N-labelled ubiquitin to confirm the backbone
assignment at pH 6.0. CD2AP SH3-A and C backbone
resonances were previously assigned at pH 6.0 (BMRB
accession numbers 16641 and 16643).
The ubiquitin-binding site on all SH3 domains site was
obtained by titrating with increasing amounts of unlabelled
ubiquitin into a 0.2 mM 15N-labelled SH3 sample. The SH3-
binding site on ubiquitin was obtained by titrating with
increasing amounts of unlabelled SH3 domain into a 0.25 mM
15N-ubiquitin sample. The progress of the titrations was
monitored by recording one-dimensional 1H and two-
dimensional 1H-15N HSQC spectra. The magnitude of the
chemical shift deviations (Δδ) was calculated using the
equation:
Δδ= ΔδHN 2+
ΔδN
6.51
2
where the difference in chemical shift is that between the
resonances corresponding to the bound and free forms at each
titration point.
All NMR data were processed using NMRPipe [19] and
analyzed by NMRView [20] and Sparky [21].
Measurement of RDCs and structure calculation
Partially aligned samples in a liquid-crystalline medium
consisting of a 5% penta-ethyleneglycol monododecyl ether
(C12E5)/hexanol mixture [22] were prepared for RDC
measurement. RDCs were measured for the CD2AP SH3-
C:Ubiquitin and CD2AP SH3-A:Ubiquitin complexes as
described elsewhere [15].
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The structure calculation of the CD2AP SH3-A and C
domains in complex with ubiquitin were carried out using the
program SCULPTOR [23] as described previously [15]. The ten
lowest target function structures (combining RDC and AIR
violation for the CD2AP SH3-A complex and RDC, AIR and
nOe violation for the CD2AP SH3-C complex) were used for
the final analysis. Validation of the structural quality was done
using PROCHECK [24,25]. H-bonds and non-bonded
interactions were obtained from analysis done with the
LIGPLOT software [26]. Salt-bridges and buried surface areas
were obtained from analysis using the EBI PISA web server
[27].
Crystallization, Crystallographic Data Collection,
Structure Determination, and Refinement of CIN85 SH3-
C
The protein was concentrated at 11.4 mM and crystallized at
4°C by vapor diffusion method using 1.8M ammonium sulphate,
0.1M Citrate pH 6.0. Crystals were stepped soaked prior to
crystal diffraction until 15-20% glycerol.
Data reduction was undertaken with Mosflm and Scala [28],
Table S2). Crystals belong to the P3 121 space group and were
solved by molecular replacement using the Sem5 C-terminal
SH3 (PDB ID: 1sem) using the program Molrep [28].
Automated model building was carried out with the program
ARP/wARP [28]. Cycles of manual and automatic refinement
were performed with Coot [29] and REFMAC [28] respectively.
The final model includes residues 270-328 from CIN85 plus 2
and 6 additional residues at the N and C terminus respectively.
All residues are in the favored regions of the Ramachandran
plot.
Fluorescence binding experiments and Isothermal
Titration Calorimetry (ITC)
Prior to the ITC experiments, fluorescence measurements
were made on a Varian, Cary Eclipse spectrofluorimeter
equipped with a peltier temperature-controlled cell holder.
Intrinsic fluorescence emission spectra were recorded at 25°C,
from 305 to 400 nm with an excitation wavelength of 298 nm to
predominantly excite the tryptophan residues present only in
the SH3 domain. Each spectrum was the result of 5
accumulations collected at a scan rate of 200 nm·min-1. First,
the spectra were recorded in the absence of ubiquitin for
CD2AP SH3-C WT (30 µM) and its mutant F324Y (40 µM) and
CD2AP SH3-A (20 µM) samples. Each protein sample was
titrated by addition of increasing volumes of a concentrated
ubiquitin stock solution (760µM) up to a final SH3: Ubiquitin
molar ratio of ~1:20. Emission fluorescence spectra were
recorded for each titration point. All spectra were blank-
corrected and normalized by protein concentration. In order to
estimate apparent affinities, corrected emission spectra were
integrated between 310 (to exclude signal scattering) and 400
nm to get the total emitted fluorescence (quantum yield), which
was then finally fitted to a model of a single set of identical
sites.
ITC experiments were performed at 25°C in a high-precision
MCS isothermal titration calorimeter and in a VP isothermal
titration calorimeter (Microcal Inc., Northampton, USA). Prior to
the experiments, WT and F324Y CD2AP SH3-C, WT CD2AP
SH3-A, as well as ubiquitin were extensively dialyzed at 4°C
against the appropriate buffer (20 mM Cacodylate, pH 6.0). All
buffers and solutions were filtered, degassed and equilibrated
to the working temperature prior to each experiment. Typically,
a 50 µM CD2AP SH3 solution in the calorimeter’s cell was
titrated with the ubiquitin stock solution (at a concentration of
about 800 µM). Due to the relatively low binding affinities,
titrations were made by using a profile of injection volumes of
the ubiquitin stock solution in order to define the titration
isotherm curve more accurately. As a blank, an independent
experiment with only buffer in the calorimeter’s cell was
performed with the same ubiquitin stock solution to determine
the corresponding heats of dilution. The dilution isotherm was
subtracted from that obtained for the titration of the protein. The
area under each peak of the net thermogram was integrated to
determine the heat produced by each binding event between
the ubiquitin and the SH3 domain after each injection.
The binding constant, Kb, and the enthalpy change of
binding, ΔHb, were determined by fitting of the binding
isotherms, using a model of binding to a single set of identical
sites as described previously [30].
Results
NMR titration experiments of CD2AP SH3-A and C
domains with ubiquitin
NMR chemical shifts of protein residues are highly sensitive
to changes in the local environment, and chemical shift
perturbations are therefore widely used to map intermolecular
interfaces of protein complexes [31]. Titrations of 15N-labeled
ubiquitin with increasing amounts of unlabeled SH3-A and C
domains at 25°C and vice versa caused a selective shift of both
amide proton and nitrogen resonances of several ubiquitin,
SH3-A (Figure 1a and c) and SH3-C residues (Figure 1b and
d), indicating a specific interaction between the two proteins.
The most significant changes in the chemical shift of the HSQC
cross-peaks of the SH3-A domain are observed at the RT loop
(residues 10-11, 13-14 and 16-18), the n-Src loop (residues
34-35), at the beginning of the β-III strand (residues 37 and 39)
and at the 310 helix and β-V strand (residues 49-56) (Figure
1e). While the titration profiles for SH3-A show intermediate
exchange behaviour, fast exchange is observed in the case of
SH3-C, indicating less tight binding for the third CD2AP SH3
domain. Substantial chemical shift differences between the free
and bound form of SH3-C are found within the RT (residues
283-288) and the n-Src (residues 302-304) loops, the
beginning of the βIII -strand (residues 307-309) and in residues
319-323 located at the beginning of the 310 helix (Figure 1f).
Different chemical shift perturbation profiles are also found
when titrating the two domains into 15N-labelled ubiquitin.
Titration with unlabelled SH3-A causes considerable changes
in the chemical shifts of residues in mainly three regions of the
protein, around Leu8 and Ile44, a common binding region for
most UBDs, and around Val70 (Figure 1g). These three
regions are affected in a similar extent. In contrast, titration of
15N ubiquitin with unlabelled SH3-C induces most significant
Alternative Ubiquitin Binding by SH3 Domains
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changes in the Ile44 and Gly76 binding regions of ubiquitin,
and very small changes are observed around Leu8 (Figure 1h).
In the light of these different results obtained for the two SH3
domains of CD2AP (A and C), we decided to investigate a
possible interaction between the second domain (SH3-B) and
ubiquitin. Chemical shift perturbations observed when titrating
15N-labeled ubiquitin with CD2AP SH3-B are very similar to that
of CD2AP SH3-A (Figure 1i), suggesting an analogous
ubiquitin binding mode for these two N-terminal SH3 domains
of CD2AP.
The three dimensional structure of the complex
between the CD2AP SH3-A and C domains with
ubiquitin
Despite the high sequence homology between the three SH3
domains of CD2AP, the different chemical shift perturbations
patterns indicate structural differences between the SH3:
Ubiquitin complexes. We have determined the structures of the
complexes CD2AP SH3-A and SH3-C in interaction with
ubiquitin in order to understand the basis of these differences
and to compare with previously determined structures of SH3:
Ubiquitin complexes (PDB entries 2JT4 and 2K6D). All
backbone resonances of the complex forms of SH3-A and C
and ubiquitin were assigned by following the cross-peaks of the
free forms upon titration with the partners and subsequently
checked using 3D HNCACB, CBCA(CO)NH and HBHA(CO)NH
experiments.
Solution structure of the SH3-A and SH3-C:Ubiquitin
complexes.  We have recently described a novel approach for
the study of weak macromolecular complexes [15] that was
applied to the SH3-C:Ubiquitin complex. Figure 2b shows a
stereo representation of the ensemble of the lowest target
function structures (combining RDC, AIR and nOe violation) of
CD2AP SH3-C in complex with ubiquitin. The ensemble shows
very good Ramachandran statistics while fulfilling the
experimental data (Table S1), with an average backbone
RMSD for residues 8-62 in SH3-C and 6-70 in ubiquitin to the
mean of 0.5 ± 0.1 Å.
A similar approach has been applied to elucidate the SH3-
A:Ubiquitin complex structure. The stereo representation of the
ensemble of the lowest target function structures (combining
RDC and AIR violations) of CD2AP SH3-A in complex with
ubiquitin is shown in Figure 2a. Structural statistics are
summarized in Table S1. The average backbone RMSD for
residues 3-56 in SH3-A and 6-70 in ubiquitin to the mean is 0.9
± 0.2 Å.
Comparison between the different SH3: Ubiquitin
complexes.  In contrast to the SH3-C:Ubiquitin complex, the
structure of the SH3-A:Ubiquitin complex has a comparable
orientation to the previously reported Sla1 SH3-3:Ubiquitin
structure (PDB entry 2JT4). The total surface area that
becomes buried upon complex formation is 1186 and 1166 Å2
for CD2AP SH3-A and C complexes, respectively, in
comparison to 1197 Å2 for the Sla1 SH3-3 complex.
Both SH3 domains bind to the same interface of ubiquitin,
which involves the Ile/Leu-rich patch, the region of the protein
that is most commonly found in complex with UBDs [9,10], but
differs mainly in the type of residues surrounding this
hydrophobic patch. Both complexes target the Ile44 binding
region on ubiquitin in a similar way via the 310 helix, including
Phe53 (Phe409 in Sla1 SH3-3) and Trp37 (Trp391 in Sla1
SH3-3). CD2AP SH3-A (Figure 3a) domain adopts a similar
orientation to that of Sla1 SH3-3 in its complex with ubiquitin
although with a small displacement towards the Leu8 ubiquitin
binding region (Figure 3d) due to contacts with the CD2AP
SH3-A n-Src loop, whereas this loop in Sla1 SH3-3 engages
the Val70 ubiquitin binding region. This displacement in the
CD2AP SH3-A:Ubiquitin complex is in agreement with the large
number of residues showing chemical shift perturbations (CSP)
in the Leu8 region of the ubiquitin molecule (Figure 1g) and
those found for the charged residues in the n-Src loop,
suggesting the formation of intermolecular interactions (Figure
1e). The RT loop targets different areas in both complexes.
While in the Sla1 SH3-3 complex it lies at the edge of the Ile44
binding region, in the CD2AP SH3-A complex the RT loop
engages the first residues in the ubiquitin C-terminus, in
agreement with the large CSP found in both regions.
The binding interface for CD2AP SH3-C (Figure 3b) engages
both the Ile/Leu-rich hydrophobic patch and the C-terminal
diglycine patch on ubiquitin but in a different way to that for
CD2AP SH3-A and Sla1 SH3-3 domains described above. This
orientation is dominated by the proximity the n-Src loop to
Arg74 and the diglycine 75-76 patch in ubiquitin consistent with
the high chemical shift perturbation observed in the C-terminus
of ubiquitin (Figure 1h). Furthermore, the Gly76 binding region
is targeted as well, although at a lower extent, through the RT
loop, as well as the Ile44 binding. Trp308 lies in the proximity of
Val70 and Leu8 areas in ubiquitin, as well as the 310 helix, but
Phe324 is not involved in any contact with ubiquitin.
Mutational Analysis of the CD2AP SH3: Ubiquitin
interactions
Ubiquitin-binding activity by SH3 domains has been linked to
the presence of a phenylalanine in equivalent positions to F409
in the Sla1 SH3-3 domain [11]. Close inspection of both
CD2AP SH3: Ubiquitin complexes indicate that phenylalanine
53 in CD2AP SH3-A (Figure 3a) is located at the core of the
hydrophobic interface, in a similar position to that occupied by
the equivalent phenylalanine in both the CIN85 SH3-C and the
Sla1 SH3-C:ubiquitin complexes (Figure 3c and 3d; PDB 2K6D
and 2JT4). In contrast, phenylalanine 324 in CD2AP SH3-C
(Figure 3b) is not directly involved in binding as it is placed at
the edge of the binding interface. Thus, mutation of this
phenylalanine to a tyrosine in the CD2AP SH3-C domain is not
expected to abolish ubiquitin binding as opposed to what was
observed for Sla1 SH3-3. Indeed 1H-15N HSQC spectra
recorded on a 15N-labeled ubiquitin sample with increasing
amounts of the SH3-C F324Y mutant (Figure 4a) indicate that
the mutant binds ubiquitin in a similar way to that observed for
the WT protein. Equivalent experiments were performed with
CD2AP SH3-A F53Y mutant. In this case though, the F53Y
mutation in CD2AP SH3-A abolished binding as observed from
the 1H-15N HSQC spectra (Figure 4b), in agreement with our
structural model and with the mutational analysis performed on
Sla1 SH3-3 [11].
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Figure 1.  Monitoring the binding between ubiquitin and the CD2AP SH3 domains and the CIN85 SH3-C domain by NMR
chemical shift perturbations.  a. 1H and 15N chemical shift changes upon titrating ubiquitin into a 15N-labelled CD2AP SH3-A
solution. Region of 1H-15N HSQC spectra recorded at increasing amounts of ubiquitin up to a final ratio of 1:1.6 (SH3: Ubi) (red to
blue). b. 1H and 15N chemical shift changes upon titrating ubiquitin into a 15N-labelled CD2AP SH3-C solution. Region of 1H-15N
HSQC spectra recorded at increasing amounts of ubiquitin up to a ratio of 1:2.4 (SH3: Ubi) (red to blue). c. 1H and 15N chemical shift
changes upon titrating CD2AP SH3-A into a 15N-labelled ubiquitin solution. Region of 1H-15N HSQC spectra recorded at increasing
amounts of CD2AP SH3-A up to a ratio of 1:1.4 (Ubi: SH3) (red to blue). d. 1H and 15N chemical shift changes upon titrating CD2AP
SH3-C into a 15N-labelled ubiquitin solution. Region of 1H-15N HSQC spectra recorded at increasing amounts of CD2AP SH3-C up to
a ratio of 1:2.5 (Ubi: SH3) (red to blue). e & f. Chemical shift deviations (Δδ) between the first and last titration point of the ubiquitin
titration into 15N-labelled CD2AP SH3-A and SH3-C, respectively. g, h, i & j. Chemical shift deviations (Δδ) between the first and last
titration point of titrating CD2AP SH3-A (G), SH3-C (H), SH3-B (I) and CIN85 SH3-C (J) into 15N-labelled ubiquitin corresponding to
a ratio of 1:1.4, 1:2.5, 1:1.2 and 1:1.1 (Ubi: SH3) respectively. Blue solid lines indicate the mean chemical shift deviations.
doi: 10.1371/journal.pone.0073018.g001
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Figure 2.  Solution structures of the complexes between ubiquitin and the first and third SH3 domains of CD2AP.  Stereo
representation of the ensemble of 10 lowest combined target function structures of the CD2AP SH3-A (a) and SH3-C (b) domains in
complex with ubiquitin. Ubiquitin is represented in blue and the SH3 domain in red. Structures were superimposed on the backbone
atoms of residues 7-70 in ubiquitin.
doi: 10.1371/journal.pone.0073018.g002
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Figure 3.  Structural comparison of different SH3: Ubiquitin complexes.  Cartoon representation of the lowest target function or
lowest energy structure of different SH3: Ubiquitin complexes. a. CD2AP SH3-A:Ubiquitin complex. Ubiquitin is represented in blue
and CD2AP SH3-A in green. b. CD2AP SH3-C:Ubiquitin complex. Ubiquitin is represented in blue and CD2AP SH3-C in red. c.
Sla1 SH3-3 in complex with ubiquitin (PDB entry 2JT4; ubiquitin in blue, Sla1 SH3-3 in magenta). d. CIN85 SH3-C in complex with
ubiquitin (PDB entry 2K6D; ubiquitin in blue, CIN85 SH3-C in cyan). Phenylalanine and tryptophan residues equivalent to F53 and
W41 in CD2AP SH3-A are given in stick representation and coloured in orange in all SH3 domains for clarity. All complexes were
superimposed on the backbone atoms of residues 7-70 of ubiquitin.
doi: 10.1371/journal.pone.0073018.g003
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To confirm our NMR studies we performed fluorescence and
Isothermal Titration Calorimetry (ITC) experiments on WT and
the F324Y mutant of CD2AP SH3-C with ubiquitin (Figure S1).
Both SH3-C variants bind ubiquitin with a moderate but similar
affinity with a Kd of 12 ± 2 µM and 24 ± 3 µM for the WT and
the F324Y mutant, respectively. WT CD2AP SH3-A binds
ubiquitin with substantially higher affinity, Kd of 1.9 ± 0.3 µM
(Figure S1).
Effect of the extension of the ubiquitin C-terminus in
SH3 binding
Hicke and co-workers showed that some of the ubiquitin
interacting SH3 domains bind significantly better to ubiquitin
when GST was covalently attached to its C-terminus, including
the CIN85 SH3-C domain and the amphiphysin SH3 domains
[11]. We investigated whether such behaviour is also found for
the CD2AP SH3-A and SH3-C domains and whether this is
somehow related to the difference observed in the ubiquitin-
binding mode. Figure 5a shows NMR-detected titrations of non-
Figure 4.  Mutational study of the ubiquitin binding by the CD2AP SH3-A and C domains and the CIN85 SH3-C
domain.  Region of 1H-15N HSQC spectra recorded at increasing amounts of the CD2AP or CIN85 SH3 mutant (red to blue). a. 1H
and 15N chemical shift changes upon titrating the CD2AP SH3-C F324Y mutant into a 15N-labelled ubiquitin sample up to a ratio of
1:0.9 (Ubi: SH3). b. 1H and 15N chemical shift changes upon titrating the CD2AP SH3-A F53Y mutant into a 15N-labelled ubiquitin
sample up to a ratio of 1:1 (Ubi: SH3). c. 1H and 15N chemical shift changes upon titrating the CIN85 SH3-C wild type form into a
15N-labelled ubiquitin sample up to a ratio of 1:1 (Ubi: SH3). d. 1H and 15N chemical shift changes upon titrating the CIN85 SH3-C
F322Y mutant into a 15N-labelled ubiquitin sample up to a ratio of 1:1.2 (Ubi: SH3). e. 1H and 15N chemical shift changes upon
titrating the CD2AP SH3-C T283A mutant into a 15N-labelled ubiquitin sample up to a ratio of 1:1.4 (Ubi: SH3). f. 1H and 15N
chemical shift changes upon titrating the CD2AP SH3-C E302K + T303 deletion mutant into a 15N-labelled ubiquitin sample up to a
ratio of 1:1.1 (Ubi: SH3). g and h. Electrostatic surface representation of the interaction between the ubiquitin C-terminus and the n-
Src loop of the WT CD2AP SH3-C and the CD2AP SH3-C E302 + T303 deletion mutant respectively. Ubiquitin R74 side chain is
represented in blue sticks for clarity.
doi: 10.1371/journal.pone.0073018.g004
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His tagged ubiquitin versus C-terminal His-tagged ubiquitin into
15N-labelled SH3-C. Although no chemical shift difference of
the His-tag is observed in the 1H-15N HSQC between the free
and bound forms and no differences are found in the ubiquitin
areas targeted by the SH3 domain (Figure 5b), one order of
magnitude higher Kd values are obtained for the titration of
SH3-C domain with non His-tagged ubiquitin. In contrast, such
a significant difference in affinity is not observed in ubiquitin
binding by the CD2AP SH3-A domain, by the highly
homologous CIN85 SH3-A (68% identity) and by Sla1 SH3-3
[11]. In light of these results, and due to the higher CIN85 SH3-
C affinity to C-terminal GST-tagged ubiquitin reported before
[11], a NMR detected titration was carried out with unlabelled
CIN85 SH3-C and 15N-labelled C-terminal His-tagged ubiquitin
(Figure 4c). Interestingly, our NMR titrations suggest
significantly tighter binding as well as different areas affected in
ubiquitin upon binding compared to those previously reported
by Forman-Kay and co-workers using non-tagged ubiquitin [12]
(Figure 1). Furthermore, the ubiquitin areas targeted in this
work are very similar to the CD2AP SH3-C titration. According
to these results and the high sequence identity (53.3%)
between the two SH3-C domains, we produced the CIN85
F322Y SH3-C mutant and titrated increasing amounts of it into
15N labelled ubiquitin. Although it was stated that this mutant
abolishes ubiquitin binding due to the replacement of the key
Phe322 residue as in Sla1 SH3-3 [12], we observed binding
with a similar affinity to that observed for the wild type form
(Figure 4d), indicating that CIN85 SH3-C displays a
comparable behaviour to CD2AP SH3-C towards ubiquitin
binding.
High resolution X-ray structure of the free CIN85 SH3-C
domain
As we indicated before, the mutation of Phe322 to a tyrosine
in the CIN85 SH3-C domain does not abolish ubiquitin binding.
However, in the structure of this complex (PDB 2K6D, Figure
3c) this Phe is located at the heart of the binding interface. As
the CIN85 SH3-C:Ubiquitin complex was calculated starting
from a homology model of the mouse CIN85 SH3-C domain
(PDB 2DA9), which might have biased the structure
determination of the complex, we have solved the high
resolution structure of CIN85 SH3-C domain using X-ray
crystallography at a resolution of 2.05 Å (Figure S2a and b).
The determined structure is very similar to the recently
published NMR structure ( [32], PDB 2K9G), with a backbone
RMSD of 0.623 Å, but significantly different to the CIN85 SH3-
C in complex with ubiquitin (PDB 2K6D), with a backbone
RMSD of 1.307 Å (Figure S2c).
Discussion
Ubiquitin is known to regulate a wide variety of cellular
activities ranging from transcriptional regulation to cell
signalling and membrane trafficking. Many cellular activities of
ubiquitin are known to be mediated by mono- rather than poly-
ubiquitin, and its functions are deciphered by various ubiquitin-
binding proteins. Recently, it was found that SH3 domains
constitute a new, distinct type of ubiquitin-binding domains [11].
The structure of the complex between Sla1 SH3-3 and ubiquitin
shows that the ubiquitin binding surface largely overlaps with
the canonical binding surface for proline-rich ligands and as in
many other ubiquitin-binding motifs, the SH3 domain engages
the Ile44 hydrophobic patch of ubiquitin [13]. A key affinity and
specificity determinant for ubiquitin-binding was appointed to
Figure 5.  The effect of a C-terminal tag in ubiquitin on SH3 binding.  a. Titration curve monitored by NMR chemical shift
perturbations of T283 (black) and E303 (red) in CD2AP SH3-C. The upper curves correspond to titrations with C-terminal His-
tagged ubiquitin, while the lower curves correspond to titrations with non-tagged ubiquitin. b. Comparison of the chemical shift
deviations (Δδ) between the first and last titration point of titrating 15N-labelled CD2AP SH3-C with C-terminal His-tagged ubiquitin
(green) and non-tagged ubiquitin (red).
doi: 10.1371/journal.pone.0073018.g005
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be Phe409 of Sla1, located at the heart of the hydrophobic
interface in the SH3-ubiquitin complex, and a tyrosine residue
at that position was found to abrogate ubiquitin binding.
We previously described a new method to use NMR RDCs to
obtain the solution structure of the complex between ubiquitin
and the SH3-C domain of CD2AP [15]. In the current work, we
have also used RDCs to obtain the solution structure of the
complex between ubiquitin and the first (SH3-A) domain of
CD2AP. In this domain, the mutation of Phe53 (equivalent to
Phe409 in Sla1 SH3-3) to tyrosine abolishes ubiquitin binding
similarly to what was observed for Sla1 SH3-3. In contrast, the
mutation of the corresponding phenylalanine residue in CD2AP
SH3-C only has a minor effect on ubiquitin binding as observed
in both the NMR and ITC titration experiments. The results
obtained here demonstrate that the two SH3 domains from the
same adaptor protein show alternative modes of ubiquitin
binding. The intriguing question remaining is which residues
and/or what region of a particular ubiquitin-binding SH3 domain
determine the mode and the orientation of binding to ubiquitin
and furthermore, whether this difference in binding mode is
related to a difference in function.
The distinct interactions between SH3 domains and ubiquitin
can be rationalized by analyzing the surfaces of both proteins.
Figure 6c shows that the CD2AP SH3-C binding surface is
mainly negatively charged, with a shallow and highly negatively
charged groove between the RT and n-Src loops, in contrast
with the less polar and smoother surface at the complex
interface in CD2AP SH3-A (Figure 6a) and Sla1 SH3-3. A close
inspection of the disposition of the different SH3: Ubiquitin
structures reveals that the main differences between both
binding modes reside in the interactions between polar
residues in the RT and n-Src loops and the ubiquitin C-
terminus.
Comparison of the amino acid sequences of CD2AP SH3-A
and C, Sla1 SH3-3 and CIN85 SH3-C domains (Figure S3)
shows that the residues found in the RT loop are generally
alike, except for the presence of two polar residues at positions
281 (Thr) and 283 (Thr) in CD2AP SH3-C that correspond to a
negatively charged and a hydrophobic residue respectively in
CD2AP SH3-A and Sla1 SH3-3 domains. In both cases the RT
loop targets the edge of the Ile44 binding region in ubiquitin,
although in the CD2AP SH3-A domain it also targets the first
residues of the ubiquitin C-terminus with the n-Src loop. In fact,
and despite the high flexibility of the ubiquitin C-terminus, a
close disposition of both is found in all the structures of the
ensemble (Figures 2A and 6). Bigger differences are observed
within the n-Src loop. This loop in CD2AP and CIN85 SH3-C is
one residue longer, resulting in a different position of the
sidechains and creating a shallow and highly negatively
charged groove with the RT loop, accommodating the ubiquitin
C-terminus on its surface. The disposition of the CD2AP SH3-C
n-Src amino acid sidechains towards the groove results as well
in fewer contacts to the Leu8 ubiquitin binding region, that are
only possible by shifting this region towards the n-Src loop.
Finally, this causes a big structural rearrangement of the 310
helix with respect to the free CD2AP SH3-C structure, all
resulting in Phe324 being outside the binding interface. In
contrast, the orientation of the CD2AP SH3-A domain n-Src
loop permits a close disposition to the Leu8 binding region in
ubiquitin, shifting the complex interface towards this area of
ubiquitin when compared with the CD2AP SH3-C and Sla1
SH3-3 complexes.
To rationalize the importance of the n-Src loop over the RT
loop in the CD2AP SH3-C:Ubiquitin interaction, we constructed
two CD2AP SH3-C mutants, one in which Thr283 in the RT
loop was mutated to alanine, and one in which Glu302 in the n-
Src loop was mutated into a lysine together with the deletion of
Thr303. The latter mutant thus becomes more similar to the
Sla1 SH3-3 domain in terms of charge and length of the n-Src
loop. No significant differences in ubiquitin binding were found
between the WT and the T283A mutant (Figure 4e), similarly to
what was previously reported for the glutamate to alanine
mutation at the equivalent position in Sla1 SH3-3 [11]. In
contrast, the E302K + T303 deletion mutant completely
eliminates ubiquitin binding (Figure 4f), thus pointing to the n-
Src loop as the key region responsible for this ubiquitin binding
mode. To discard that deficiency of ubiquitin binding resulted
from an unfolded SH3-C domain due to the mutation, 1D 1H
experiments were recorded throughout the NMR titration
experiments. These spectra indicate proper folding of the SH3-
C mutant.
We constructed a structural model of the CD2AP SH3-C
E302K + T303 deletion mutant using the program Modeller
[33]. The shorter n-Src loop pushes this region further away
from the ubiquitin C-terminus (Figure 4g and h). Due to the
shorter length of the loop, the replaced Glu302 to a Lys points
outwards of the groove, thus eliminating any hydrophobic
interaction with Gly75 and hindering the interaction of Gly304
with the Arg74 in ubiquitin. Moreover, the rearrangement
introduces some positively charged areas in the binding
interface that result in unfavourable contacts with Arg74 in
ubiquitin. As stated before, positively charged and non-polar
residues compose the same regions in CD2AP SH3-A and in
Sla1 SH3-3. These residues are not located in the proximity of
the binding interface. Both differences in length and charge of
the n-Src loop are thus related to the different ubiquitin binding
modes exhibited by SH3 domains. All mutations performed in
ubiquitin binding SH3 domains and their effects are
summarized in Figure S3.
Hicke and co-workers showed that some of the ubiquitin
interacting SH3 domains bind significantly better to ubiquitin
when GST was covalently attached to its C-terminus, including
the CIN85 SH3-C domain and the amphiphysin SH3 domains
[11]. The importance of the ubiquitin C-terminus is not novel in
SH3: Ubiquitin binding as observed in the interaction between
Endophilin-A SH3 and the Parkin ubiquitin like protein (Ubl)
[34] and in the interaction between NcK SH3-3 and ubiquitin
[16]. Although no structure of the complex with ubiquitin was
reported, the authors showed that Nck SH3-3 domain interacts
with ubiquitin even though it possesses a tyrosine residue
instead of a phenylalanine at the key position 73. Interestingly
enough, chemical shift perturbations (CSP) suggest that the
ubiquitin C-terminus is directly involved in Nck SH3 binding,
although the CSP pattern found in ubiquitin and the Nck SH3-3
domain interaction is different to that reported for the Sla1
SH3-3 and that for the CD2AP SH3-C ubiquitin binding modes.
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In the case of the interaction between Endophilin-A SH3 and
the Parkin Ubl the relative orientation is considerably different
than that of Sla1 SH3-3 or CD2AP SH3-C. The Parkin Ubl C-
terminus adopts an extended β strand conformation that
mimics a proline-rich ligand. Moreover, Arg75 mutation to a Gly
residue, as in ubiquitin, completely abolishes binding, whereas
Lys76 to Gly mutation only diminishes the interaction [34].
Furthermore, the Endophilin-A SH3 domain is considerably
shifted towards the C-terminus compared with the CD2AP
SH3-C domain. Therefore, CD2AP SH3-C:Ubiquitin interaction
constitutes a different ubiquitin binding mode than those
described for Sla1 SH3-3 domain and for Endophilin-A SH3
domains.
The presence of a C-terminal tag in ubiquitin has a strong
effect on the ubiquitin affinity for CD2AP SH3-C and CIN85
SH3-C but not for CD2AP SH3-A domain. We previously
showed a marked decrease in the flexibility of the ubiquitin C-
terminus in the SH3-C complex using spin relaxation data [35].
The C-terminal extension results in rigidification of the ubiquitin
C-terminus, lowering the entropy cost associated with the
decrease of its flexibility upon binding, as recently observed for
the BAR SH3-Ubl interaction [34]. The changes in internal
dynamics in the free ubiquitin molecules would therefore be
reflected in favourable changes in conformational entropy, and
thus an increase in binding affinity, as it has been shown for
the catabolite activator protein-DNA binding [36]. The higher
affinity to C-terminal elongated ubiquitin molecules was
previously reported for CIN85 SH3-C and amphiphysin SH3
domains binding to ubiquitin [11], although in this case the His-
tag was replaced by a GST-tag. These domains, like CD2AP
SH3-C, posses a longer n-Src loop, as well as negatively
charged residues at the edge of it, suggesting that they bind
Figure 6.  SH3: Ubiquitin binding interfaces.  Surface representations of the free forms of CD2AP SH3-A (a), ubiquitin (b) and
CD2AP SH3-C (c), showing the surface-charge distribution. Electrostatic surface representation of the orientation of the CD2AP
SH3-A and C complexes with ubiquitin (green and orange respectively), zooming in at the SH3 RT-loop (d & g respectively), SH3 n-
Src loop (e & h respectively) and ubiquitin C-terminus (f & i respectively). Ubiquitin residues with chemical shift perturbation higher
than the mean are coloured in magenta. Charged residues with high CSP are represented in coloured sticks (blue and red for
positively and negatively charged) for clarity. The electrostatic surface representation was drawn with Pymol (www.pymol.org) using
a Poisson-Boltzmann electrostatics calculation [40].
doi: 10.1371/journal.pone.0073018.g006
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ubiquitin in a similar manner to that of CD2AP SH3-C when
binding C-terminal tagged ubiquitin. This suggests that the
higher affinity observed for C-terminal tagged ubiquitin
constitutes a feature of this binding mode.
Titrations of the highly homologous (53.3% identity) CIN85
SH3-C into 15N-labelled C-terminal His-tagged ubiquitin (Figure
1j) revealed a CSP pattern very similar to the one exhibited by
CD2AP SH3-C (Figure 1f). Furthermore, the F322Y mutation in
the CIN85 SH3-C domain does not diminish ubiquitin binding
(Figure 4c and d), and taking also into account the higher
affinity of CIN85 SH3-C towards C-terminal tagged ubiquitin
molecules, we can conclude that CIN85 and CD2AP SH3-C
domains present a similar ubiquitin binding mode. These
results are in contrast to the relative orientation of the CIN85
SH3-C domain and ubiquitin in the previously determined
complex (Figure 3d [12]); the difference might be the result of a
distortion due to the G76C mutation and the incorporation of a
MTSL molecule into the ubiquitin C-terminus, as well as due to
PRE constraints sensitive to minor alternate conformations
[15]. This incorrect orientation might also be caused by the use
of a structural model of the free CIN85 SH3-C domain, which
was based on the mouse CIN85 SH3-C domain (PDB 2DA9)
We, therefore solved the crystal structure of CIN85 SH3-C and
show that this X-ray structure as well as the recently published
NMR structure (PDB 2KG9 [17]) are substantially different to
the same domain in complex with ubiquitin (Figure S2c). The
backbone RMSD of both NMR and X-ray structures with
respect to the CIN85 SH3-C domain in the ubiquitin complex
are 1.307 and 1.219 Å respectively, much higher than
compared to CD2AP SH3-C, with a backbone RMSD of 0.765
Å. Importantly, differences are mainly found in the RT and n-
Src loops, both crucial for the interaction with ubiquitin.
Interestingly, Kay and coworkers suggested that CIN85 SH3-C
presents two distinct conformations when bound to ubiquitin
[14]. The first binding mode, originally named (PL)1, presents a
lower network of contacts involving Leu8 and Ile44. In contrast,
His68 and Gly47–Gln49 establish contacts with the RT loop, as
well as the C-terminal region of ubiquitin, in perfect agreement
with the chemical shift perturbation pattern found in CIN85
SH3-C binding to C-terminal tagged ubiquitin. Moreover, no
contact involving the key Phe322 is observed, suggesting that
CIN85 SH3-C is able to bind ubiquitin in both the canonical
(Sla1 SH3-3) and the CD2AP SH3-C mode.
Cbl E3 ubiquitin protein ligase mediates polyubiquitination of
EGFR and monoubiquitination of CIN85 to control endosomal
sorting and degradation of receptor tyrosine kinases. CD2AP
and CIN85 become monoubiquitinated via interaction with Cbl/
Cbl-b [37] upon activation of the EGF receptor. This activation
leads to phosphorylation of Cbl and subsequent binding of the
SH3-A and/or SH3-B domains of CIN85/CD2AP to the proline-
rich region at the C-terminal region of c-Cbl [38]. Forman-Kay
and co-workers have shown that the triple Phe-to-Tyr mutant in
full-length CIN85 is still able to self-ubiquitinate like the WT
protein, and that even in the absence of EGF stimulation CIN85
is ubiquitinated [12]. The authors suggested that in this case,
none of the three CIN85 SH3 domains is able to grab ubiquitin
and hence they negatively regulate CIN85/CD2AP
ubiquitination. However, we have shown in our work that CIN85
SH3-C binds ubiquitin in the same way as CD2AP SH3-C,
independent if a phenylalanine or tyrosine residue is present.
Therefore, even though having a tyrosine at position 322, the
triple Phe-to-Tyr mutant CIN85 is still capable of binding
ubiquitin via its SH3-C.
CD2AP SH3-A and B domains are able to tightly bind free
ubiquitin. For CD2AP and CIN85 SH3-C domains however,
tight binding requires the ubiquitin molecule be attached via its
C-terminus to another protein, avoiding in this way the
interaction of this domain with free ubiquitin molecules present
in the cellular milieu. CD2AP/CIN85 ubiquitination takes place
via a covalent bond between the ubiquitin C-terminus and the
sidechain of a lysine of the intact carboxyl terminus of CD2AP/
CIN85 [8,37]. This process is controlled by Cbl together with
the polyubiquitination of EFGR in a trimeric complex. It has
been observed for different proteins containing UBDs that their
own monoubiquitination results in more favourable
intramolecular interactions between this attached ubiquitin
molecule and their own UBDs [39]. The ubiquitin molecule
covalently attached to CD2AP/CIN85 could then be an ideal
candidate for the interaction with the SH3-C domain. This
possible interaction may constitute the specific mechanism
suggested by Dikic and co-workers [37] that prevents further
addition of ubiquitin chains to monoubiquitinated CIN85.
Recognition of the CIN85-ubiquitin by SH3-C might then either
protect against polyubiquitination, which would ensure
degradation with EGFR, or protect against deubiquitination to
prevent recycling of the CIN85 to the cytoplasmic pool.
Additional experiments are required to verify this hypothesis.
It was previously established that the three CD2AP/CIN85
SH3 domains negatively regulate CD2AP/CIN85 ubiquitination
[12]. However, we show that the third SH3 domain of CD2AP/
CIN85 binds ubiquitin with a different mechanism. On the basis
of our mutational and structural work we conclude that CD2AP
and CIN85 SH3-C domain interaction with ubiquitin constitutes
a new ubiquitin-binding mode involved in the regulation of the
ubiquitination level of CD2AP and CIN85 adaptor proteins to
ensure CD2AP/CIN85 degradation upon EFG activation, and
thus changes the previously established mechanism of EGF-
dependent CD2AP/CIN85 mono-ubiquitination.
Accession Codes
Coordinates of the CD2AP SH3-A and C complexes with
ubiquitin have been deposited in the PDB and chemical shifts
and RDC values in the BMRB with accession numbers 2MCN
and 19447 and 2LZ6 and 18737, respectively. Coordinates and
structure factors of the free CIN85 SH3-C domain have been
deposited with accession numbers 2YDL and r2ydlsf,
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